Lightstone Ventures related stories
All articles and analysis
Foundry Innovation & Research 1 raises $7.5 mlnFoundry Innovation & Research 1 Ltd (Fire 1) said April 12 that it closed its Series B financing at $7.5 Existing investors including Lightstone Ventures and New Enterprise Associates, as well as Medtronic, participated in the round. Foundry also named Conor Hanley as its President and CEO. Dublin-based FIRE1 is a medical device company.
Worldwide fundraising briefsFrom Mucker in LA to Atomico in the UK, a recap of worldwide fundraising news
- Abingworth, Canaan lead $43 mln Series B for Tizona Therapeutics
Tizona Therapeutics Inc, a company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases, raised $43 million in Series B funding. Abingworth and Canaan Partners led the round with participation from Lightstone Ventures and existing Series A investors, including MPM Capital, Amgen Ventures, Astellas Venture Management and InterWest Partners.
- Lightstone closes Singapore-focused fund with investments from Temasek, EDBI
Lightstone Ventures closed a $50 million fund focused on investing in Singapore-based life sciences technologies and companies. Temasek, an investment company based in Singapore, and EDBI, the corporate investment arm of the Singapore Economic Development Board, have invested in the fund.
Reading the venture tea leaves for 2016Here are the trends we at Sapphire Ventures have been closely watching and what we think they imply for 2016.
- Catabasis Pharmaceuticals taps ex-Lightstone and ATV general counsel for team
Cambridge, Massachusetts-based drug developer Catabasis Pharmaceuticals has appointed Deirdre Cunnane as senior vice president, general counsel. Previously, Cunnane was general counsel at Lightstone Ventures and Advanced Technology Ventures.
- Ra Pharmaceuticals racks up $58.5 mln Series B
Cambridge, Massachusetts-based biotech company Ra Pharmaceuticals has closed $58.5 million in Series B funding. RA Capital Management, Novo Ventures and Lightstone Ventures led the round with participation from other investors that included Rock Springs Capital Limulus Venture Partners, New Enterprise Associates, Novartis Venture Fund, Morgenthaler Ventures and Amgen Ventures. In conjunction with the funding, Rajeev Shah of RA Capital and Peter Tuxen Bisgaard of Novo Ventures (US) Inc have been added to Ra Pharma’s board of directors.
- IPO aftermarket: Shopify launches, but biotech rules
Through the end of May, a total 31 VC-backed companies have launched IPOs on the NYSE or Nasdaq exchanges